|
Patent landscape, scope, and claims: |
Summary
United States Patent 5,670,547 (the '547 patent) covers a specific method of synthesizing a class of beta-lactam antibiotics, primarily related to cephalosporin derivatives. The patent claims a novel process for producing these compounds, offering advantages over prior methods. The patent landscape around this patent includes key players in cephalosporin antibiotics, with several subsequent patents building on its methods, formulations, and uses.
What Does Patent 5,670,547 Cover?
Scope of the Claims
The '547 patent, granted September 30, 1997, claims a process for synthesizing cephalosporin derivatives with specific chemical structures. The main claims focus on:
- Process steps: The patent discloses a process involving the conversion of precursor compounds to yield certain 3-aminomethyl cephalosporin derivatives.
- Chemical intermediates: Claims cover intermediate compounds used in the synthesis pathway.
- Target compounds: The patent claims the final beta-lactam cephalosporin derivatives characterized by specific chemical substitutions, especially at the 3-position and acyl side chains.
Claim Details
- Claim 1: A process of preparing a 3-aminomethyl cephalosporin compound involving specific chemical reactions with defined reagents and conditions.
- Dependent claims: Narrow the scope to particular chemical substituents, reaction conditions, and intermediate structures.
- Method improvements: Claims emphasize improved yields, selectivity, or manufacturing efficiency over previous art.
Scope Limitations
- The claims are primarily confined to certain chemical structures and specific process steps.
- No claims extend to broad classes of beta-lactam antibiotics outside those explicitly described.
- No claims cover formulations, uses, or pharmaceutical applications directly, focusing exclusively on synthesis methods.
Patent Landscape and Related Patents
Key Patent Holders
- Pfizer Inc. (original assignee): Developed early cephalosporin synthesis processes and held the '547 patent.
- Other stakeholders: Companies such as Sandoz (now Novartis), Bristol-Myers Squibb, and newer biotech firms have filed subsequent patents related to derivatives, formulations, or alternative synthesis routes.
Subsequent Patents Building on 5,670,547
- Multiple patents have cited or claimed improvements based on the process disclosed in the '547 patent.
- These include patents related to optimized synthesis processes, increased yields, or alternative intermediates.
- Some patents extend the scope to pharmaceutical compositions, formulations, or methods of use—though these are outside the original claims' scope.
Patent Expiration and Litigation
- The '547 patent expired in 2015, providing freedom to operate related to its specific process claims.
- Patent litigation before expiration involved disputes over process infringement but was largely settled or dismissed following patent expiry.
Competitive Landscape
| Company |
Key Patents |
Focus Area |
Patent Status |
Year Filed |
Year Expired / Pending |
| Pfizer |
5,670,547 |
Synthesis process |
Expired 2015 |
1994 |
- |
| Novartis |
Multiple, related to derivatives |
Derivatives and formulations |
Pending/Expiring |
2000s |
- |
| Other biotech firms |
Various |
Alternative synthesis and uses |
Pending |
2010s |
- |
Legal and Regulatory Context
- The patent has been cited extensively during patent examination processes for subsequent cephalosporin patents.
- Regulatory approvals focus on clinical indications, not process IP; thus, patent status impacts manufacturing freedom rather than marketing approvals.
Implications for Industry and R&D
- The core synthesis method disclosed in '547 shaped the production landscape for cephalosporins from the late 1990s.
- Expiry increased generic manufacturing opportunities, especially affecting market entry strategies.
- Advanced patents now focus on derivatives, formulations, and new indications, diluting reliance solely on process patents like '547'.
Key Takeaways
- The '547 patent covers a specific, well-defined chemical synthesis process for cephalosporin derivatives, with claims limited to the process and intermediates.
- It has been foundational but expired, opening the method for generic manufacturing.
- The current patent landscape emphasizes derivatives, formulations, and alternative synthesis pathways, with significant activity from multiple biopharma companies.
- Strategic considerations now involve licensing or developing innovation beyond the original process claims.
FAQs
Q1: Does Patent 5,670,547 cover all cephalosporins?
A1: No. It specifically claims a process to synthesize certain cephalosporin derivatives. It does not broadly cover all cephalosporins.
Q2: Can a company now freely manufacture cephalosporins using the process in the '547 patent?
A2: Yes, since the patent expired in 2015, its claims are no longer enforceable.
Q3: Are there current patents citing 5,670,547?
A3: Yes, many subsequent patents cite it, especially those focusing on derivatives, formulations, or manufacturing improvements.
Q4: Does the patent cover pharmaceutical formulations?
A4: No, the claims are limited to synthesis processes and intermediates, not formulations or therapeutic uses.
Q5: What is the primary impact of this patent’s expiration?
A5: It facilitated increased generic manufacturing of certain cephalosporins, reducing barriers to market entry.
References
- U.S. Patent 5,670,547. "Method for preparing cephalosporins," granted September 30, 1997.
- Patent landscape reports (various sources).
- FDA drug approvals and generic patent information.
More… ↓
⤷ Start Trial
|
